https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-27 / Oncotarget 2017 Sep;8(40):67439-67456
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-27 / Oncotarget 2017 Sep;8(40):67439-674562017-06-27 00:00:002017-06-27 00:00:00Survival of metastatic melanoma patients after dendritic cell vaccination correlates with expression of leukocyte phosphatidylethanolamine-binding protein 1/Raf kinase inhibitory protein
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-20 / Oncotarget 2017 Jun;8(25):41538-41548
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-20 / Oncotarget 2017 Jun;8(25):41538-415482017-06-20 00:00:002019-02-15 08:51:22A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-07 / Biomed Res Int 2017;2017:5618174
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-07 / Biomed Res Int 2017;2017:56181742017-06-07 00:00:002017-06-07 00:00:00Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-06 / Clin Transl Oncol 2017 Dec;19(12):1489-1497
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-06 / Clin Transl Oncol 2017 Dec;19(12):1489-14972017-06-06 00:00:002017-06-06 00:00:00Influence of ovarian cancer type I and type II microenvironment on the phenotype and function of monocyte-derived dendritic cells
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-05 / J Clin Oncol 35, 2017 (suppl; abstr 3089)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-05 / J Clin Oncol 35, 2017 (suppl; abstr 3089)2017-06-05 12:09:062019-07-17 12:09:34Association of autologous AdHER2 dendritic cell vaccination with antitumor activity and number of circulating tumor cells.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-03 / J Clin Oncol 35, 2017 (suppl; abstr TPS4153)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-03 / J Clin Oncol 35, 2017 (suppl; abstr TPS4153)2017-06-03 00:00:002017-06-03 00:00:00A phase III, double-blind, randomized clinical trial comparing S-1 in combination with DC vaccine loaded with WT1 peptides (TLP0-001) or placebo for the patients with advanced pancreatic cancer refractory to standard chemotherapy.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-03 / Arch. Virol. 2017 Sep;162(9):2705-2713
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-03 / Arch. Virol. 2017 Sep;162(9):2705-27132017-06-03 00:00:002019-02-15 08:39:31Evaluation of the oncolytic potential of RB Mukteshwar vaccine strain of Newcastle disease virus (NDV) in a colon cancer cell line (SW-620)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-01 / Clin Adv Hematol Oncol 2017 Jun;15(6):466-477
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-01 / Clin Adv Hematol Oncol 2017 Jun;15(6):466-4772017-06-01 00:00:002017-06-01 00:00:00Immunotherapy in urothelial cancer, part 1: T-cell checkpoint inhibition in advanced or metastatic disease
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-01 / JAMA Oncol 2017 Jun;3(6):841-849
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-01 / JAMA Oncol 2017 Jun;3(6):841-8492017-06-01 00:00:002017-06-01 00:00:00Oncolytic Viruses in Cancer Treatment: A Review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2017-06-01 / Neuro-oncology 2017 06;19(6):796-807
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2017-06-01 / Neuro-oncology 2017 06;19(6):796-8072017-06-01 00:00:002019-02-15 08:36:06Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma
